Hier finden Sie wissenschaftliche Publikationen aus den Fraunhofer-Instituten.

Utilizing BMP-2 muteins for treatment of multiple myeloma

: Seher, A.; Lagler, C.; Stühmer, T.; Müller-Richter, U.D.A.; Kübler, A.C.; Sebald, W.; Müller, T.D.; Nickel, J.

Fulltext ()

PLoS one. Online journal 12 (2017), No.5, Art. e0174884, 18 pp.
ISSN: 1932-6203
Deutsche Forschungsgemeinschaft DFG
KFO 216
Journal Article, Electronic Publication
Fraunhofer IGB ()

Multiple myeloma (MM) represents a haematological cancer characterized by the pathological hyper proliferation of antibody-producing B-lymphocytes. Patients typically suffer from kidney malfunction and skeletal disorders. In the context of MM, the transforming growth factor beta (TGF beta) member Activin A was recently identified as a promoter of both accompanying symptoms. Because studies have shown that (b) under bar one (m) under bar orphogenetic (p) under bar rotein (BMP)2-mediated activities are counteracted by Activin A, we analysed whether BMP2, which also binds to the Activin A receptors ActRII and ActRIIB but activates the alternative SMAD-1/5/8 pathway, can be used to antagonize Activin A activities, such as in the context of MM. Therefore three BMP2 derivatives were generated with modified binding activities for the type II (ActRIIB) and/or type I receptor (BMPRIA) showing either increased or decreased BMP2 activity. In the context of MM these BMP2 muteins show two functionalities since they act as a) an anti-proliferative/apoptotic agent against neoplastic B-cells, b) as a bone-formation promoting growth factor. The molecular basis of both activities was shown in two different cellular models to clearly rely on the properties of the investigated BMP2 muteins to compete for the binding of Activin A to the Activin type II receptors. The experimental outcome suggests new therapeutic strategies using BMP2 variants in the treatment of MMrelated pathologies.